BioLineRx accesses second tranche of $20 million under previously announced $40 million non-dilutive debt financing agreement with BlackRock
PUBLIC · BLRXApr 10, 2024
Amount Raised
$20
Round Type
Pre-Seed
Tel AvivBiotechnologyHealthcareHealth CareTherapeuticsBiopharmaresearch
Investors
Black Rock
Description
BioLineRx Ltd. has drawn-down the second tranche of $20 million under its previously announced $40 million non-dilutive debt financing agreement with funds and accounts managed by BlackRock. The proceeds will be used to further accelerate uptake of APHEXDA® in stem cell mobilization, life-cycle expansion activities in sickle cell disease, and motixafortide metastatic pancreatic cancer program.
Company Information
Company
BioLineRx Ltd
Location
2 HaMa'ayan Street
Tel Aviv, Tel Aviv District, Israel
About
BioLineRx is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma. BioLineRx is advancing a pipeline of investigational medicines for patients with sickle cell disease, pancreatic cancer, and other solid tumors. Headquartered in Israel, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing discoveries move beyond the bench to the bedside.
Fundz sees it the moment BioLineRx Ltd raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Tel AvivBiotechnologyHealthcareHealth CareTherapeuticsBiopharmaresearch